Effect of Omacor on Triglycerides in HIV Infected Subjects
Launched by SOLVAY PHARMACEUTICALS · Jan 11, 2008
Trial Information
Current as of July 24, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Triglycerides between 200 and 800
- • diagnosed HIV infection
- • following HAART therapy
- Exclusion Criteria:
- • other malignant disease
- • not compliant
- • allergy against fish oil
- • soy or olive oil
About Solvay Pharmaceuticals
Solvay Pharmaceuticals is a global biopharmaceutical company dedicated to improving patient health through innovative research and development. As a subsidiary of Solvay, a multinational chemical and advanced materials company, Solvay Pharmaceuticals focuses on delivering transformative therapies across various therapeutic areas, including central nervous system disorders, cardiovascular health, and women's health. Committed to scientific excellence and patient-centric solutions, the company collaborates with healthcare professionals and regulatory bodies to advance clinical trials and bring safe, effective medications to market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bochum, , Germany
Hannover, , Germany
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Global Clinical Director Solvay
Study Director
Solvay Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials